We are committed to finding a cure for WM.


Mayo Clinic Update on Diagnosis and Treatment of WM






This open source article was recently published in the American Journal of Hematology. 

Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management


  • Morie A. Gertz
  • First published: 




Member in the news!

Ron Ternoway


WMFC Member was featured in the QEII Time – The Chronicle. The article discusses the support he has received from the QEII Hematology Clinic.


Priceless: Innovation and teamwork make the QEII’s Hematology Clinic a world-class resource for Nova… Continue reading

Board of Directors Announcement




 The Waldenstrom’s Macroglobulinemia Foundation of Canada would like to extend a sincere thank you to Bert Visheau, a Board of Director member since 2003, for his dedication and support to the WMFC. Bert has stepped down after… Continue reading

Article: The Rarity of WM Challenging

Treatment options are limited for patients with Waldenstrom’s macroglobulinemia (WM), says Morie A. Gertz, MD. Combination therapies offer a potential solution, but the rarity of the disease is an obstacle. The disease occurs in roughly 4 patients per million, per… Continue reading

Health Canada Approves IMBRUVICA

IMBRUVICA® is an oral, once-daily, single-agent therapy associated with a durable response in patients with this rare B-cell lymphoma

TORONTOMay 12, 2016 /CNW/ – Janssen Inc. announced today that Health Canada has issued… Continue reading